| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3276 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3764 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3803 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3865 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3915 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3985 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.3990 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4088 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4562 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4656 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4688 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4793 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4827 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4842 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4875 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.4927 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5054 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5200 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5306 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5335 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5345 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5380 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5399 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5532 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5539 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5583 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5786 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5825 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5870 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5915 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5973 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.5990 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6068 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6099 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6172 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6260 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6270 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6322 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6358 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6419 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6478 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6535 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6707 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6721 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6723 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6811 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6873 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6920 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.6993 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7055 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7202 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7279 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7329 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7377 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7386 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7507 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7563 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7891 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.7924 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8016 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8118 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8136 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8164 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8192 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8274 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8305 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8332 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8334 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8375 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8390 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8432 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8622 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8670 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8706 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8730 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8783 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.8908 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9010 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9027 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9103 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9132 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9198 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9236 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9242 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9298 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9384 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9458 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9469 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9552 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9605 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9637 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9669 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 0.9711 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0000 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0064 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0113 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0227 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0289 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0331 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0419 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0577 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0646 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0937 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.0939 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1160 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1323 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1360 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1607 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1698 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1704 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1751 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1764 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1766 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1767 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.1938 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2039 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2062 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2174 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2203 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2291 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2315 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2556 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2623 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.2750 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3012 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3055 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3064 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3092 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3128 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3253 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3277 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3338 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3368 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3466 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3468 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3485 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3666 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3764 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3900 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3921 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3962 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.3976 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4117 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4151 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4217 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4306 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4371 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4481 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4608 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4781 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4789 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4865 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4887 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.4912 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5218 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5276 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5321 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5333 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5363 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5837 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5847 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.5987 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.6222 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.6565 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.6975 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7048 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7397 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7604 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7725 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7759 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7773 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.7827 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.8164 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.8204 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.8473 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.8802 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.8998 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.9142 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.9676 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 1.9689 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.0206 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.0400 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.1611 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.2619 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.2852 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.3764 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | gamma-glutamylleucine | 2.6073 | scaled units | Placebo | BASELINE |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|